Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. SPY
4. ODFL
5. USO
6. AZN
7. LAD
8. ROIV
9. ORCL
10. CRCL

Go back to Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1149.36 --0 (-0%)
Previous Close $1149.36    52 Week High $88.16 
Open $1149.36    52 Week Low $67.88 
Day High $1149.36    P/E 266.06 
Day Low $1149.36    EPS $4.32 
Volume 19,618